Celyad Oncology SA
CLYYF
$0.25
-$0.10-28.57%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | -48.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | -48.10% | |||
| Cost of Revenue | -- | -100.00% | |||
| Gross Profit | 0.00% | 20.59% | |||
| SG&A Expenses | -0.43% | 28.84% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.43% | -5,913.45% | |||
| Total Operating Expenses | 0.43% | -162.34% | |||
| Operating Income | -0.43% | 162.78% | |||
| Income Before Tax | -0.43% | 226.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -0.43% | 226.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.43% | 226.28% | |||
| EBIT | -0.43% | 162.78% | |||
| EBITDA | -3.34% | 168.57% | |||
| EPS Basic | -0.50% | 218.69% | |||
| Normalized Basic EPS | -0.55% | 157.78% | |||
| EPS Diluted | -0.58% | 202.58% | |||
| Normalized Diluted EPS | -0.64% | 149.84% | |||
| Average Basic Shares Outstanding | 0.00% | 6.52% | |||
| Average Diluted Shares Outstanding | 0.00% | 23.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||